Printer Friendly

Bristol-Myers Squibb announces planned divestiture of HIV R&D Portfolio to ViiV Healthcare.

M2 PHARMA-December 18, 2015-Bristol-Myers Squibb announces planned divestiture of HIV R&D Portfolio to ViiV Healthcare


Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) reported on Thursday that it has entered into two individual agreements to divest its pipeline of investigational HIV medicines consisting of a number of programmes at different stages of discovery, preclinical and clinical development to ViiV Healthcare.

As part of the agreements, ViiV will pay to Bristol-Myers Squibb upfront payments totaling USD350m with potential development and regulatory milestone payments of up to USD518m for the clinical assets and up to USD587m for the discovery and pre-clinical programmes.

Following the approval and commercialisation of the products, ViiV Healthcare will pay tiered royalties, pay sales-based milestone payments of up to USD750m for each of the clinical assets as well as up to USD700m for each of the discovery and pre-clinical programmes.

The Bristol-Myers Squibb clinical stage HIV pipeline reportedly includes an attachment inhibitor (BMS-663068) that is being investigated in Phase III as a therapeutic option for heavily treatment-experienced patients as well as a maturation inhibitor (BMS-955176) that is being investigated in Phase IIb development for treatment-naive and treatment-experienced patients. The pipeline includes active preclinical and discovery stage programmes.

Upon closing, ViiV Healthcare will manage and resource the acquired development programmes, Bristol-Myers Squibb will continue to provide at ViiV Healthcare's expense certain research and development support and 20 Bristol-Myers Squibb employees are being offered the opportunity to transfer to ViiV Healthcare.

Closing is expected during the first half of 2016, subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 18, 2015
Previous Article:Oculus Innovative Sciences receives US FDA approval for Microcyn SebDerm Gel for seborrheic dermatitis, with anticipated launch in June quarter 2016.
Next Article:Midatech Pharma to buy Zuplenz from Galena Biopharma for USD3.75m in cash.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters